Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Simulations Plus Inc (SLP)

Simulations Plus Inc (SLP)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,429,694
  • Shares Outstanding, K 19,965
  • Annual Sales, $ 41,590 K
  • Annual Income, $ 9,330 K
  • 60-Month Beta -0.03
  • Price/Sales 35.82
  • Price/Cash Flow 98.63
  • Price/Book 9.25
Trade SLP with:

Options Overview

Details
  • Implied Volatility 61.68%
  • Historical Volatility 54.30%
  • IV Percentile 57%
  • IV Rank 15.52%
  • IV High 190.73% on 03/16/20
  • IV Low 37.97% on 10/12/20
  • Put/Call Vol Ratio 0.00
  • Today's Volume 8
  • Volume Avg (30-Day) 55
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 157
  • Open Int (30-Day) 443

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 02/28/21
See More
  • Average Estimate 0.14
  • Number of Estimates 2
  • High Estimate 0.14
  • Low Estimate 0.13
  • Prior Year 0.12
  • Growth Rate Est. (year over year) +16.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
68.94 +4.03%
on 02/23/21
90.92 -21.12%
on 02/08/21
-6.77 (-8.63%)
since 01/26/21
3-Month
53.75 +33.43%
on 12/02/20
90.92 -21.12%
on 02/08/21
+16.30 (+29.41%)
since 11/25/20
52-Week
26.00 +175.85%
on 03/16/20
90.92 -21.12%
on 02/08/21
+35.28 (+96.82%)
since 02/26/20

Most Recent Stories

More News
Simulations Plus and the University of Pittsburgh Drug Discovery Institute Receive SBIR Grant Funding for Large Molecule Safety Collaboration

Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that its DILIsym Services (DSS) division...

SLP : 71.72 (+0.15%)
Simulations Plus to Participate in BTIG Virtual MedTech, Digital Health, Life Science and Diagnostic Tools Conference

Simulations Plus, Inc. (Nasdaq: SLP), a premier provider of simulation and modeling software and consulting services for pharmaceutical discovery and development, today announced that Shawn O'Connor, chief...

SLP : 71.72 (+0.15%)
Simulations Plus Releases GastroPlus(R) Version 9.8.1

Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemical, and consumer goods industries, today announced that it has...

SLP : 71.72 (+0.15%)
Simulations Plus Enters Agreement with Distributor in China

Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemical, and consumer goods industries, today announced that it has...

SLP : 71.72 (+0.15%)
Simulations Plus Expands Marketing and Sales Operations in South America Through Partnership with the Institute of Pharmaceutical Sciences

Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemical, and consumer goods industries, today announced that it has...

SLP : 71.72 (+0.15%)
Simulations Plus Awards Infrastructure Improvement Grant to Makerere University Department of Pharmacology and Therapeutics

Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of population pharmacokinetic and pharmacodynamic modeling and simulation services, today announced that its Cognigen division has awarded a grant...

SLP : 71.72 (+0.15%)
Simulations Plus (SLP) Stock Down Despite Q1 Earnings Beat

Simulations Plus (SLP) fiscal first-quarter results reflect solid software and service revenue growth. However, coronavirus crisis affected renewals.

NVDA : 548.58 (+3.06%)
AAPL : 121.26 (+0.22%)
SLP : 71.72 (+0.15%)
GOOGL : 2,021.91 (+0.30%)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Simulations Plus, Inc. - SLP

New York, New York--(Newsfile Corp. - January 12, 2021) -  Levi & Korsinsky announces it has commenced an investigation of Simulations Plus, Inc. (NASDAQ: SLP) concerning possible breaches of fiduciary...

SLP : 71.72 (+0.15%)
Simulations Plus to Present at 23rd Annual Needham Virtual Growth Conference

Simulations Plus, Inc. (Nasdaq: SLP), a premier provider of simulation and modeling software and consulting services for pharmaceutical discovery and development, today announced that chief executive officer...

SLP : 71.72 (+0.15%)
Simulations Plus Enters New Funded Collaboration to Improve Lung Exposure Models for Pulmonary Infection Treatments

Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemical, and consumer goods industries, today announced that it has...

SLP : 71.72 (+0.15%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Simulations Plus, Inc., is a premier developer of groundbreaking drug discovery and development simulation software, which is licensed to and used in the conduct of drug research by major pharmaceutical and biotechnology companies worldwide. They have two other businesses, Words+, Inc. and FutureLab,...

See More

Key Turning Points

3rd Resistance Point 77.37
2nd Resistance Point 75.68
1st Resistance Point 73.70
Last Price 71.72
1st Support Level 70.03
2nd Support Level 68.34
3rd Support Level 66.36

See More

52-Week High 90.92
Last Price 71.72
Fibonacci 61.8% 66.12
Fibonacci 50% 58.46
Fibonacci 38.2% 50.80
52-Week Low 26.00

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar